Tetsuro Yoshimaru

Tetsuro Yoshimaru

Auto-generated profile, based on publicly available information

Tetsuro Yoshimaru

Institute of Advanced Medical Sciences Tokushima University Tokushima 770-8503 Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
TYTetsuro Yoshimaru
Tetsuro Yoshimaru
MOMasaya Ono
Masaya Ono
YBYoshimi Bando
Yoshimi Bando
YCYi-An Chen
Yi-An Chen
KMKenji Mizuguchi
Kenji Mizuguchi
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
Approximately 70% of breast cancer cells express oestrogen receptor alpha (ERα). Previous studies have shown that the Brefeldin A-inhibited guanine nucleotide-exchange protein 3–prohibitin 2 (BIG3-PHB2) complex has a crucial role in these cells. However, it remains unclear how BIG3 regulates the suppressive activity of PHB2. Here we demonstrate that BIG3 functions as an A-kinase anchoring protein that binds protein kinase A (PKA) and the α isoform of the catalytic subunit of protein phosphatase 1 (PP1Cα), thereby dephosphorylating and inactivating PHB2. E2-induced PKA-mediated phosphorylation of BIG3-S305 and -S1208 serves to enhance PP1Cα activity, resulting in E2/ERα signalling activation via PHB2 inactivation due to PHB2-S39 dephosphorylation. Furthermore, an analysis of independent cohorts of ERα-positive breast cancers patients reveal that both BIG3 overexpression and PHB2-S39 dephosphorylation are strongly associated with poor prognosis. This is the first demonstration of the mechanism of E2/ERα signalling activation via the BIG3–PKA–PP1Cα tri-complex in breast cancer cells.

20 July 2021 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
TYTetsuro Yoshimaru
Tetsuro Yoshimaru
YNYusuke Nakamura
Yusuke Nakamura
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
Breast cancer is a heterogeneous disease that develops through a multistep process via the accumulation of genetic/epigenetic alterations in various cancer-related genes. Current treatment options for breast cancer patients include surgery, radiotherapy, and chemotherapy including conventional cytotoxic and molecular-targeted anticancer drugs for each intrinsic subtype, such as endocrine therapy and antihuman epidermal growth factor receptor 2 (HER2) therapy. However, these therapies often fail to prevent recurrence and metastasis due to resistance. Overall, understanding the molecular mechanisms of breast carcinogenesis and progression will help to establish therapeutic modalities to improve treatment. The recent development of comprehensive omics technologies has led to the discovery of driver genes, including oncogenes and tumor-suppressor genes, contributing to the development of molecular-targeted anticancer drugs. Here, we review the development of anticancer drugs targeting cancer-specific functional therapeutic targets, namely, MELK (maternal embryonic leucine zipper kinase), TOPK (T-lymphokine-activated killer cell-originated protein kinase), and BIG3 (brefeldin A-inhibited guanine nucleotide-exchange protein 3), as identified through comprehensive breast cancer transcriptomics.

1 October 2008 in Clinical Immunology
Verified
Journal Article
Closed access
TMTakashi Matsui
Takashi Matsui
SNSatoshi Nunomura
Satoshi Nunomura
TSToshibumi Shimokawa
Toshibumi Shimokawa
TYTetsuro Yoshimaru
Tetsuro Yoshimaru
CRChisei Ra
Chisei Ra

1 May 2024 in ChemistryEurope
Verified
Journal Article
Open access
DKDaishiro Kobayashi
Daishiro Kobayashi
MDMasaya Denda
Masaya Denda
JHJunya Hayashi
Junya Hayashi
KHKota Hidaka
Kota Hidaka
YKYutaka Kohmura
Yutaka Kohmura
AOAkira Otaka
Akira Otaka
A method was developed that enables the magnesium chloride (MgCl2)‐activated S‐acetamidomethyl cysteine sulfoxide (Cys(Acm)(O)) to induce the sp2(C−H) sulfenylation of the indole of Trp residues. The reaction operates under mild acidic conditions using acetic acid or an ionic liquid to give the Trp‐sulfenylated products. Other than Trp, all other proteinogenic amino acids are unreactive to the sulfenylation conditions. We demonstrated the successful application of this reaction to various peptides, including lysozyme. Furthermore, we achieved the Trp‐modification of a monoclonal antibody by a MgCl2‐mediated reaction in an acidic ionic liquid. The resulting antibody exhibited antibody performance comparable to the parent protein. The amide moiety in the Acm group contributes to the difference in chemical behaviors between S‐Acm and S‐p‐methoxybenzyl (MBzl)‐protected cysteine sulfoxides. This is because the S‐Acm sulfoxide is converted to S‐chlorocysteine responsible for Trp‐sulfenylation under less acidic conditions than those required for the reaction of S‐MBzl sulfoxide. Based on this rationale, we prepared a linker possessing S‐Acm and S‐MBzl oxide moieties and subjected the linker to heterodimerization of DNA‐binding MYC and MAX peptides containing a Trp handle. The one‐pot/stepwise Cys‐Trp conjugation between the linker and DNA‐binding peptides allowed the generation of a heterodimeric MYC/MAX DNA binder.

25 October 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
KUKeiji Uchiyama
Keiji Uchiyama
KHKosei Hagiwara
Kosei Hagiwara
YMYosuke Matsushita
Yosuke Matsushita
TYTetsuro Yoshimaru
Tetsuro Yoshimaru
MOMasaya Ono
Masaya Ono
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
Increased expression of the polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6), an O-glycosyltransferase, has been reported to play a crucial role in mammary carcinogenesis. Here, we demonstrate that GALNT6 O-glycosylates Glucose-regulated protein 78/Binding immunoglobulin protein (GRP78/Bip), a key regulator of the unfolded protein response (UPR), by adding N-acetylgalactosamine (GalNAc), thereby modulating its stability in breast cancer cells. Functional inhibition of either GALNT6 or GRP78/Bip suppressed the proliferation of the luminal-type breast cancer cell line, ZR-75-1, understanding their importance in tumor cell growth. We further found that GRP78/Bip, which is primarily localized in the endoplasmic reticulum (ER), is transported to the Golgi apparatus under the ER stress conditions, where it undergoes O-glycosylation at Thr203 by the Golgi-resident GALNT6. Substitution of Thr203 with alanine inhibited the binding of GRP78/Bip to IRE1, an ER stress sensor, suggesting that the O-glycosylation at Thr203 in GRP78/Bip facilitates sustained activation of the UPR. These findings define the GALNT6-GRP78/Bip axis as a novel mechanism driving persistent UPR activation and tumor cell adaptation to ER stress, offering a potential new therapeutic target for luminal-type breast cancers.

1 May 2024 in ChemistryEurope
Verified
Journal Article
Open access
DKDaishiro Kobayashi
Daishiro Kobayashi
MDMasaya Denda
Masaya Denda
JHJunya Hayashi
Junya Hayashi
KHKota Hidaka
Kota Hidaka
YKYutaka Kohmura
Yutaka Kohmura
AOAkira Otaka
Akira Otaka